Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

作者：Binghe Xu, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wěi Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Yongmei Yin, Yanxia Shi, Yueyin Pan, Yongsheng Wang, Weimin Xie, Min Yan, Yunjiang Liu, Ping Yan, Fei Wu, Xiaoyu Zhu, Jianjun Zou · 发表于：Nature Medicine · 年份：2021 · DOI：10.1038/s41591-021-01562-9 · 被引用次数：176 · 研究领域：Advanced Breast Cancer Therapies、Chronic Lymphocytic Leukemia Research、Cancer-related Molecular Pathways